It’s not known whether Repatha (evolocumab) is safe to use while pregnant or breastfeeding. Certain factors may determine whether you should use the drug during this time. It’s not known ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Repatha (evolocumab) is a prescription drug used to lower cholesterol and decrease serious heart-related risks. The drug comes as a liquid solution that you inject under your skin. It’s usually ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

The massive pharmacy benefit manager plans to stop requiring coverage authorizations for roughly 80 drugs used to treat ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

The company's cash payout ratio is about 47%, giving it plenty of room to grow its dividend. Here's the bottom line: Amgen is an excellent stock for long-term, income-seeking investors.

Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and rare disease drugs, mostly products added from the Horizon acquisition, are driving sales.

The company has a deep lineup of medicines that includes growth drivers like Repatha, a drug used to decrease the risk of heart attacks in certain patients; asthma therapy Tezspire; Teppezza ...